Chugai sales and marketing update

Chugai launched Alecensa alectinib in Japan to treat unresectable, recurrent or advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). The ALK inhibitor is usually dosed at 300 mg twice daily, with a 20 mg capsule priced at Y901.70 ($8.57) and a 40 mg capsule priced at Y1,763.90 ($16.76). In July, Japan became the first country to approve the drug. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), which is the majority owner of Chugai, has rights to the compound elsewhere. ...